Jonathan Salmond

Queen Elizabeth Hospital, NHS Greater Glasgow and Clyde

Papers

2

Total Citations

20

H-Index

2

About

Jonathan Salmond is a clinical researcher focused on improving surgical outcomes for men with localized prostate cancer, with a particular emphasis on preserving quality of life after robotic-assisted radical prostatectomy (RARP). His major contribution centers on the NeuroSAFE PROOF trial, a landmark single-blinded, multi-centre, randomized controlled trial designed to evaluate the NeuroSAFE technique—a method that uses intraoperative frozen section analysis of the neurovascular bundles to guide nerve-sparing during RARP. By comparing this approach to standard RARP, Salmond’s work aims to reduce the common and debilitating side effects of postoperative erectile dysfunction and urinary incontinence, which significantly impact patients’ quality of life. The study protocol, published in 2022, has already garnered over 20 citations, reflecting its importance in the field of urologic oncology. Salmond’s research is notable for its rigorous IDEAL stage 3 design, which sets a high standard for evidence-based surgical innovation. His efforts are helping to refine surgical techniques that balance oncologic control with functional preservation, offering hope for better long-term outcomes for prostate cancer patients.

Research Focus

Key Achievements

2
H-Index
2
Papers
20
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
NeuroSAFE PROOF: study protocol for a single-blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NeuroSAFE robotic-assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer
15 citations · 2022
📈 Most Prolific Year: 2022 (2 Papers)
🤝 Key Collaborators: 30
🏛 Institutions: Queen Elizabeth Hospital, NHS Greater Glasgow and Clyde

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago